KONTAN.CO.ID - JAKARTA. The weakening trend of the Indonesian rupiah against the US dollar could potentially have a significant impact on the sustainability of the pharmaceutical business in Indonesia. According to observations on the Google Finance page, the rupiah broke through the level of Rp 16,057 per US dollar on Monday (15/4) afternoon. Elfiano Rizaldi, the Executive Director of the Pharmaceutical Company Association (GP), believes that the impact of the weakening rupiah on the pharmaceutical industry greatly depends on how long this currency correction trend lasts.
Baca Juga: Freeport Responds to Indonesian Government's Demand for 61% Share Ownership Control If the rupiah continues to weaken after the Eid holiday or until next month, the national pharmaceutical industry is clearly threatened. Understandably, almost 90% of raw materials for pharmaceutical products such as drugs still have to be imported from abroad. So far, there are only a dozen or so raw materials for pharmaceuticals that can be produced domestically. Even then, it is not entirely or 100% local content considering the production capacity of the national pharmaceutical industry is still relatively small.